(Beijing News) The China National Drug Administration has the conditions to approve the two domestic crown disease oral drugs.
According to the announcement issued on Sunday (January 29), the official website of the State Drug Administration, the official conducts emergency review and approval in accordance with the relevant provisions of the Drug Management Law, and conducts emergency review and approval procedures.
The two crown diseases approved by the latest conditions are a type of innovative drugs declared by Hainan Xianyou Pharmaceutical Co., Ltd.He and Shanghai Wangshi Biomedical Technology Co., Ltd. declared a class of innovative medicines at hydrocelatic acid (product name: Minidi).
The two drugs above are orally oral small -molecular coronal virus infection drugs for treatment of adult patients with mild moderate crown disease.The State Drug Administration requires that the holders of the listing permit will continue to carry out relevant research work, complete the requirements for the qualified conditions within a time limit, and submit subsequent research results in a timely manner.
Earlier, China has approved three crown disease oral medicines, namely the domestic Azf fixed tablet, as well as the imported Paxlovid and the Molnupiravir of Molnupiravid (China).
